Sutton TL, Walker BS, Billingsley KG, et al. - Researchers sought to determine factors related to post-recurrence survival (PRS) as well as progression-free survival (PFS) among patients with gastrointestinal stromal tumors (GIST). They obtained clinicopathologic and outcome data, and computed disease-free interval (DFI) from the end of curative-intent oncologic therapy until recurrence. Median DFI was estimated to be 14 months (interquartile range 2–26 months); a DFI ≤24 months and a DFI > 24 months was detected in 51 (63%) and 30 (37%) patients, respectively. Increased 10-year PRS and 10-year PFS was found in patients with a DFI >24 months vs those with a DFI ≤24 months. Findings demonstrated an independent link of DFI with oncologic outcomes in recurrent GIST. Experts suggest the likely usefulness of DFI in treatment planning. Indolent disease biology may be signified by recurrence post-24 months, and for this, additional treatment including metastasectomy may be beneficial.